Johnson & Johnson's Darzalex combination approved for bone marrow cancer

2026-03-10 10:40:22

Abstract generation in progress

Johnson & Johnson’s Darzalex, developed in collaboration with Genmab, has received approval from the US FDA for treating recurrent or refractory bone marrow cancer. The approval applies to patients who have undergone at least one previous treatment. The article indicates that access to the full content requires a subscription.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.